Risk factors of acute graft-versus-host disease (AGVHD) after allogeneic bone marrow transplantation using an matched unrelated donor (MUD) and prophylaxis with taclorimus (FK506) and methotrexate (MTX)

被引：0
|
作者：
Iguchi, T
Okamoto, S
Mori, T
Watanabe, R
Sato, N
Nagayama, H
Takayama, N
Ikeda, Y
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P654
引用
收藏
页码：S172 / S173
页数：2
相关论文
共 50 条
  • [21] Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation
    Yu, C
    Storb, R
    Deeg, HJ
    Graham, TC
    Schuening, FG
    Huss, R
    Seidel, K
    Fitzsimmons, WE
    BONE MARROW TRANSPLANTATION, 1996, 17 (04) : 649 - 653
  • [22] Glucocorticoids failed to enhance the effect of FK506 and methotrexate (MTX) on prevention of graft-versus-host disease (GVHD) after DLA-nonidentical, unrelated canine marrow transplantation.
    Yu, C
    Storb, R
    Deeg, HJ
    Fitzsimmons, WE
    Sale, G
    BLOOD, 1996, 88 (10) : 3654 - 3654
  • [23] FK506 TO PREVENT GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC MARROW TRANSPLANTATION (AMT) USING UNRELATED MARROW DONORS (UMD)-A PHASE-II STUDY
    FAY, JW
    COLLINS, RH
    PINEIRO, LA
    NEMUNAITIS, JJ
    ARO, R
    FITZSIMMONS, W
    BLOOD, 1993, 82 (10) : A420 - A420
  • [24] Risk factors of developing acute graft-versus-host disease (AGVHD) after HLA-matched unrelated donor (MUD) transplantation - Importance of maintaining the blood level of tacrolimus early after transplantation
    Okamoto, S
    Iguchi, T
    Mori, T
    Watanabe, R
    Aisa, Y
    Shimizu, T
    Yokoyama, A
    Ikeda, Y
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 47 - 48
  • [25] COMBINATION OF CYCLOSPORINE AND METHOTREXATE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA
    MRSIC, M
    LABAR, B
    BOGDANIC, V
    NEMET, D
    PAVLETIC, Z
    PLAVSIC, F
    DOBRIC, I
    MARUSIC, M
    FRANCETIC, I
    KASTELAN, A
    KALENIC, S
    VRTAR, M
    MARKULINGRGIC, L
    AURER, I
    BONE MARROW TRANSPLANTATION, 1990, 6 (02) : 137 - 141
  • [26] PHARMACOLOGICAL PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION
    SCHWINGHAMMER, TL
    BLOOM, EJ
    CLINICAL PHARMACY, 1993, 12 (10): : 736 - 761
  • [27] Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
    Ratanatharathorn, V
    Nash, RA
    Przepiorka, D
    Devine, SM
    Klein, JL
    Weisdorf, D
    Fay, JW
    Nademanee, A
    Antin, JH
    Christiansen, NP
    van der Jagt, R
    Herzig, RH
    Litzow, MR
    Wolff, SN
    Longo, WL
    Petersen, FB
    Karanes, C
    Avalos, B
    Storb, R
    Buell, DN
    Maher, RM
    Fitzsimmons, WE
    Wingard, JR
    BLOOD, 1998, 92 (07) : 2303 - 2314
  • [28] FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED MARROW DONOR (UMD) TRANSPLANTATION
    FAY, JW
    PINEIRO, L
    COLLINS, RH
    STEIN, B
    ARO, RM
    FITZSIMMONS, WE
    BLOOD, 1994, 84 (10) : A708 - A708
  • [29] Prevention of graft-versus-host (GVHD) after unrelated marrow transplantation therapy (UMT) using tacrolimus (FK506) and prednisone.
    Fay, JW
    Agura, E
    Collins, R
    Pineiro, L
    BLOOD, 1996, 88 (10) : 1660 - 1660
  • [30] Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies
    Uberti, JP
    Silver, SM
    Adams, PT
    Jacobson, P
    Scalzo, A
    Ratanatharathorn, V
    BONE MARROW TRANSPLANTATION, 1997, 19 (12) : 1233 - 1238
12345